Tamoxifen for prevention of breast cancer: Extended long-term follow-up of the IBIS-I breast cancer prevention trial

The Lancet Oncology

Volumn 16, Issue 1, 2015, Pages 67-75

  Cuzick, Jack ^a   Sestak, Ivana ^a   Cawthorn, Simon ^b   Hamed, Hisham ^c   Holli, Kaija ^d   Howell, Anthony ^e   Forbes, John F ^f  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^e Genesis Breast Cancer Prevention Centre   (United Kingdom)

^f UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PLACEBO; TAMOXIFEN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADOLESCENT; AGED; ARTICLE; AUSTRALIA; BELGIUM; BREAST CANCER; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CONTROLLED STUDY; FEMALE; FINLAND; FOLLOW UP; HUMAN; INTRADUCTAL CARCINOMA; IRELAND; MAJOR CLINICAL STUDY; NEW ZEALAND; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SPAIN; SWITZERLAND; TUMOR INVASION; UNITED KINGDOM; ADULT; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CHEMISTRY; CLINICAL TRIAL; DRUG ADMINISTRATION; EUROPE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTICARCINOGENIC AGENTS; AUSTRALIA; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEW ZEALAND; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; RISK ASSESSMENT; RISK FACTORS; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84925807420     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)71171-4     Document Type: Article

References (19)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Cuzick J, Baum M Tamoxifen and contralateral breast cancer. Lancet 1985, 2:282.
3. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005, 97:1652-1662.
4. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998, 90:1371-1388.
5. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007, 99:283-290.
6. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002, 360:817-824.
7. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007, 99:272-282.
8. Veronesi U, Maisonneuve P, Rotmensz N Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 2003, 95:160-165.
9. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998, 352:98-101.
10. Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 2013, 381:1827-1834.
11. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998, 352:93-97.
12. Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 2007, 99:727-737.
13. Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 2014, 383:1041-1048.
14. Cox D Analysis of survival data 1984, Chapman & Hall, New York.
15. Cox DR Regression models and life tables. J R Stat Soc 1972, 34:187-220.
16. Schoenfeld D Chi-squared goodness-of-fit tests for the proportional hazard regression model. Biometrika 1980, 67:145-153.
17. Kaplan EL, Meier P Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
18. Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378:771-784.
19. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003, 361:296-300.